 |
 |
|
The Managing Directors and Principals of TFG have over 100 years of pharmaceutical and life science industry experience, and together with the team of seasoned TFG Senior Consultants, Consultants, Associates and Analysts bring expertise from not only the supplier side of the healthcare industry but also in-depth experience from the academia, payer, provider and investment sectors of the industry as well.
This breadth of complementary professional experiences across the staff members at TFG allows us to provide multiple perspectives on the diagnosis, interpretation and solution for any given engagement.
Barry R. Frankel, Managing Director
TFG Experience
Barry founded The Frankel Group in March of 1993. Following nearly 20 years in the life science industry, Barry saw an opportunity to pull together a team of experienced professionals from suppliers, providers, banking and consulting to provide creative yet actionable strategic solutions to the pharmaceutical, biotechnology and device/diagnostics industries.
Since the founding of TFG, Barry has advised and managed a diverse range of engagements, including business strategies and franchise development strategies; the identification and valuation of acquisition, licensing and alliance candidates; R&D portfolio planning and technology platform assessments; market entry and commercialization strategies; and forward integration strategies employing internal assets, channel intermediaries and disease management initiatives. Clients have spanned multinational pharmaceutical companies, biotechnology and startup pharmaceutical organizations, device and diagnostic firms, industry intermediaries including CROs and CSOs, technology companies seeking to leverage their product platforms into life science, and industry trade and patient advocacy organizations.
Recent assignments have included: (1) a strategy to leverage drug delivery technology upstream in lead optimization to create a parallel development pathway for a multinational pharmaceutical company; (2) a global market entry strategy for a major multisource pharmaceutical company into the emerging generic biologics market; (3) a business migration strategy in multisource and drug delivery enhanced products for a specialty generics company; (4) account targeting, marketing strategy development and sales force planning for a US multisource division of a global pharmaceutical company; (5) a series of strategic advisory efforts for a public biotechnology company in determining their business strategy, acquisition identification and assessment, and commercialization organization development; and (6) a reorganization strategy for an industry trade association to better address evolving member product technologies and external global regulations.
In addition, Barry has led TFG's expansion into the venture capital area, holding an asset management advisory role with equity4life, AG, a Switzerland based venture capital firm focused on investments in biotechnology, medical device/diagnostic and health care service startups on a global basis. With the movement into a successful liquidation phase of this fund, Barry and his partners are forming a new venture investment vehicle, BioDevelopment Ventures, LP. BioDevelopment Ventures is designed to further leverage the expertise of TFG in R&D planning, licensing/acquisitions and product commercialization given its intention to apply private equity and internal development expertise to the acquisition, Phase I - II development, and industry exit of promising early-stage pharmaceutical product candidates.
Pre-TFG Experience
Prior to TFG, Barry was President of SJ Weinstein Associates, a health care marketing strategy and advertising firm, where he formulated marketing and communications strategies for some of the leading life science companies. His earlier experience included strategic planning for Pfizer Pharmaceuticals, as well as senior marketing positions at Pfizer in the anti-infective, multisource pharmaceutical and diagnostic markets. In addition, Barry was an Investment Research Officer for life science investments at Citibank.
Education
Barry holds a Masters in Business Administration with Distinction from The Wharton School of The University of Pennsylvania, and a Bachelors of Science Summa Cum Laude in Engineering from Rutgers University.
|
Lester S. Cheng, Managing Director
TFG Experience
Lester has been Partner at TFG since 1998 and has had the pleasure of advising and managing on a broad range of engagements including global business strategies, global franchise development, market entry/commercialization planning, clinical portfolio planning and target product profile assessments, channel/provider strategies, disease management initiatives, market assessment/segmentation, industry supply-demand analyses, licensing and business development, venture capital investment due diligence, and trade/patient association strategies.
Over the years, he has immersed himself in the key issues and dynamics across multiple therapeutic areas, including oncology, respiratory/allergy, infectious diseases, diabetes/metabolics, neurology, psychiatry, cardiovascular, dermatology, rheumatology, hematology, and immunology. During the past several years, he has had the opportunity to investigate a breadth of technology platforms as well, including drug delivery, diagnosis/monitoring devices, R&D enablers/tools in addition to macromolecules/biologic products. Client relationships have ranged from pharma to biotech to device/diagnostics to generic companies. Other healthcare clients have included trade organizations, patient advocacy groups, and venture capital.
Examples of Lester's recent experience include 1) an analysis of the opportunities and drivers of success within the emerging generic injectable, oncology and biologic product categories, 2) multiple target product profile assessments and prioritization for a portfolio of CNS products for a development stage company, 3) a long term franchise strategy in inflammation and immunology for a top global pharmaceutical company, 4) a pharmaceutical trade channel analysis and strategic implications assessment for a top 5 pharmaceutical company and 5) a pediatric franchise engagement for a specialty pharmaceutical company.
Pre-TFG Experience
Prior to joining TFG, Lester was at Schering-Plough Corporation in their Oncology Biotech Division. His tenure at Schering included launching the Hepatitis indications for INTRON A, business development analyses and disease management opportunity assessments and program development. Prior to that, he was in field sales with Marion Laboratories.
Education
Lester holds a BS with honors in Biochemistry from Lehigh University and an MBA with honors in Marketing and International Business from Columbia Business School.
|
Marc P. Tomassi, Managing Director
TFG Experience
Marc has managed and advised on a wide range of projects including business franchise development, product marketing strategy, business development/in-licensing, clinical development & regulatory planning, channel strategy, managed care strategy, sales planning & account targeting. Clients have consisted of large and mid-size pharmaceutical, biotechnology, generics, drug delivery, lab/diagnostics, pharmacy/distribution, CRO, e-health and telecommunication companies. Disease areas of significant focus include CNS (neurology & psychiatry), metabolics, oncology & supportive care, female health, dermatology, blood/coagulation disorders, immunology/virology and genetic disorders.
Examples of recent experience include analysis of trends in brand and multisource drug supply chain and distribution channels across the different classes-of-trade, and the formulation of novel strategies and tactical initiatives for driving revenue growth and efficiency improvements. Separately, Marc has also been focusing on the regulatory and competitive environment surrounding challenges to branded product exclusivity, and the implications these developments have for both major pharma and specialty/generic players.
Marc is also works closely with BioDevelopment Ventures, LP, a novel venture capital fund that invests directly in late preclinical stage compounds and manages their development through proof-of-concept. A major part of this role is identifying, screening and assessing a wide range of technology classes and individual validated targets as potential investment opportunities.
Pre-TFG Experience
Prior to joining TFG, Marc held management positions in strategic marketing and market research at Empire Blue Cross Blue Shield (NY). Prior to that he worked in financial analysis, utilization analysis and medical informatics with Bay State Health Care HMO (merged with Blue Cross Blue Shield of MA).
Education
Marc holds an AB in Political Science from Syracuse University, and an MBA from the Carroll School of Management at Boston College.
|
Nathan J. Dowden, Managing Director
TFG Experience
Nathan has led a wide range of strategic, financial and scientifically oriented engagements. Efforts include work in various therapeutic groups including: oncology, diabetes rheumatology, critical care, infectious disease, dermatology, interventional cardiology, pulmonology, gastroenterology, degenerative neurology, pain management, hematology, and orthopedics.
Across those areas of medicine his technology platform experience includes stem cells & tissue engineering, immunotherapeutics & tolerance (e.g., antibodies, vaccines) proteins, peptides & constructs thereof, small molecules, drug delivery and genomics.
Nathan's expertise includes forecasting & franchise strategy development, incubator & new business creation, product launch & market planning, business development & investment advisory, new product profile & clinical trial development.
Clients have included the research & development, business development, & marketing groups of top 5 global pharmaceutical and biotechnology firms. Nathan has also advised a broad array of smaller medical device, diagnostic, biopharmaceutical, and pharmaceutical firms.
Pre-TFG Experience
Prior to joining TFG Nathan was a consultant with Ernst & Young LLP where his engagement experience included Payor (Mergers & Acquisition, Operational Assessment, IT Systems), and Provider (Mergers & Acquisition, Operational Assessment). Nathan worked at Searle Pharmaceuticals in their Managed Care Strategy group and prior to that was an analyst at CIGNA Healthcare.
Education
Nathan holds an MBA with dual concentrations in Finance & Marketing from The University of Chicago.
|
David M. Gilman, Managing Director
TFG Experience
David joined TFG in 2000 and has led project teams addressing a broad range of client challenges including global therapeutic area franchise development, licensing and acquisition strategy and execution, market entry/commercialization planning, clinical development planning and target product profile assessment, market assessment/segmentation and venture capital investment due diligence.
Over recent years, David has had the opportunity to lead teams addressing basic discovery, development and commercialization related issues across multiple therapeutic areas, including oncology, hematology, respiratory/allergy, infectious diseases, neurology, psychiatry, cardiovascular, dermatology, rheumatology, and immunology. During the past several years, David has invested considerable time in exploring the convergence of the traditional small molecule pharmaceutical business with biotechnology related advances in therapeutics, diagnostics and devices. Other healthcare clients have included the application of high-tech (hardware and software) solutions within the healthcare arena, and venture capital investing.
Examples of David's recent experience include 1) a comprehensive review of the evolving biopharmaceutical sector (the convergence of large and small molecule business models) and the requirements to achieve and maintain leadership, 2) an infectious disease franchise development engagement focused on the technical, commercial and social challenges of HIV care, 3) a clinical development strategy for a company investing in anti-psychotic care, 4) a long term franchise strategy in inflammation and immunology for a top global pharmaceutical company, 5) an analysis of the opportunities and drivers of success within the emerging generic injectable, oncology and biologic product categories.
Pre-TFG Experience
Prior to joining TFG, David held marketing management positions with Johnson & Johnson Medical Inc. and 3M Healthcare focused on product development, product management and quantitative analysis. David also spent 2 years exploring the high technology sector managing a global technology sales group for American Airlines / Sabre Group.
Education
David holds a BA in East Asian History from the University of Chicago and an MBA with a concentration in Marketing from the University of Texas at Austin.
|
|
|
